Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Observational Study
. 2014 Aug;11(8):1377-83.
doi: 10.1016/j.hrthm.2014.04.039. Epub 2014 May 2.

Outcomes in African Americans undergoing cardioverter-defibrillator implantation for primary prevention of sudden cardiac death: findings from the Prospective Observational Study of Implantable Cardioverter-Defibrillators (PROSE-ICD)

Yiyi Zhang  1 , Robert Kennedy  2 , Elena Blasco-Colmenares  3 , Barbara Butcher  3 , Sanaz Norgard  3 , Zayd Eldadah  4 , Timm Dickfeld  5 , Kenneth A Ellenbogen  6 , Joseph E Marine  3 , Eliseo Guallar  1 , Gordon F Tomaselli  3 , Alan Cheng  7
Affiliations
Observational Study

Outcomes in African Americans undergoing cardioverter-defibrillator implantation for primary prevention of sudden cardiac death: findings from the Prospective Observational Study of Implantable Cardioverter-Defibrillators (PROSE-ICD)

Yiyi Zhang et al. Heart Rhythm. 2014 Aug.

Abstract

Background: Implantable cardioverter-defibrillators (ICDs) reduce the risk of death in patients with left ventricular dysfunction. Little is known regarding the benefit of this therapy in African Americans (AAs).

Objective: The purpose of this study was to determine the association between AA race and outcomes in a cohort of primary prevention ICD patients.

Methods: We conducted a prospective cohort study of patients with systolic heart failure who underwent ICD implantation for primary prevention of sudden cardiac death. The primary end-point was appropriate ICD shock defined as a shock for rapid ventricular tachyarrhythmias. The secondary end-point was all-cause mortality.

Results: There were 1189 patients (447 AAs and 712 non-AAs) enrolled. Over a median follow-up of 5.1 years, a total of 137 patients experienced an appropriate ICD shock, and 343 died (294 of whom died without receiving an appropriate ICD shock). The multivariate adjusted hazard ratio (95% confidence interval) comparing AAs vs non-AAs were 1.24 (0.96-1.59) for all-cause mortality, 1.33 (1.02, 1.74) for all-cause mortality without receiving appropriate ICD shock, and 0.78 (0.51, 1.19) for appropriate ICD shock. Ejection fraction, diabetes, and hypertension appeared to explain 24.1% (10.1%-69.5%), 18.7% (5.3%-58.0%), and 13.6% (3.8%-53.6%) of the excess risk of mortality in AAs, with a large proportion of the mortality difference remaining unexplained.

Conclusion: In patients with primary prevention ICDs, AAs had an increased risk of dying without receiving an appropriate ICD shock compared to non-AAs.

Keywords: African American; All-cause mortality; Implantable cardioverter-defibrillator; Sudden cardiac death; implantable cardioverter-defibrillator shock.

PubMed Disclaimer

Conflict of interest statement

Conflicts of Interest Disclosures: ZE reports receiving honorarium from St. Jude Medical. KAE reports research grant support and honoraria from Boston Scientific, Medtronic and St. Jude Medical. AC reports receiving honoraria from Biotronik, Boston Scientific, Medtronic and St. Jude Medical. All other authors have no relevant disclosures to report.

Figures

Figure 1
Figure 1. Multivariable adjusted hazard ratios (95% CI) for mortality comparing African-Americans (AA) with non-AA, by pre-specified subgroups
Hazard ratios were adjusted for age, sex, enrollment center, education, smoking status, body mass index, ejection fraction, NYHA class, ischemic cardiomyopathy, atrial fibrillation, diabetes, hypertension, and chronic kidney disease. Deviation to the right of 1 indicates higher mortality in AAs in the indicated subgroup.
See this image and copyright information in PMC

References

    1. Moss AJ, Zareba W, Hall WJ, Klein H, Wilber DJ, Cannom DS, Daubert JP, Higgins SL, Brown MW, Andrews ML. Prophylactic implantation of a defibrillator in patients with myocardial infarction and reduced ejection fraction. N Engl J Med. 2002 Mar 21;346:877–883. - PubMed
    1. Bardy GH, Lee KL, Mark DB, et al. Amiodarone or an implantable cardioverter-defibrillator for congestive heart failure. N Engl J Med. 2005 Jan 20;352:225–237. - PubMed
    1. Buxton AE, Lee KL, Fisher JD, Josephson ME, Prystowsky EN, Hafley G. A randomized study of the prevention of sudden death in patients with coronary artery disease. Multicenter Unsustained Tachycardia Trial Investigators. N Engl J Med. 1999 Dec 16;341:1882–1890. - PubMed
    1. Kadish A, Dyer A, Daubert JP, et al. Prophylactic defibrillator implantation in patients with nonischemic dilated cardiomyopathy. N Engl J Med. 2004 May 20;350:2151–2158. - PubMed
    1. Hohnloser SH, Kuck KH, Dorian P, Roberts RS, Hampton JR, Hatala R, Fain E, Gent M, Connolly SJ. Prophylactic use of an implantable cardioverter-defibrillator after acute myocardial infarction. N Engl J Med. 2004 Dec 9;351:2481–2488. - PubMed

Publication types